Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4221-4230 Newer>

The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
The Motley Fool October 11, 2007 Rich Smith	Quick Take: Johnson & Johnson Jilts Junior In response to an FDA warning of rare instances of abuse, Johnson & Johnson, Wyeth and Novartis all stop selling their infant cough syrups.
The Motley Fool October 11, 2007 Billy Fisher	An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007.
IEEE Spectrum October 2007 Josh Romero	Alternative Knife for Plastic Surgery After Weight Loss The recent increase in weight-loss surgeries has created a secondary demand for procedures like lower-body lifts, and an emerging market for companies that make surgical devices.
The Motley Fool October 10, 2007 Brian Lawler	Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
Reason October 2007 Ronald Bailey	Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest."
Reason October 2007 Ronald Bailey	Ties That Bind Considering that thousands of clinical trials are undertaken every year, it's reassuring that the pharmaceutical industry's critics can turn up only a few instances of bad behavior caused by financial conflicts of interest during the last two decades.
<Older 4221-4230 Newer> Return to current articles.